Epidermal growth factor receptors siRNA-conjugated collagen modified gold nanoparticles for targeted imaging and therapy of lung cancer

Materials Today Advances

Cheng-Ming Tang¹  Chen-Feng Chiu²  Ru-Huei Fu³  Shan-hui Hsu⁴  Hsien-Hsu Hsieh⁴  Huey-Shan Hung⁴  Chun-An Yeh⁵  Wei-Hsiang Fang⁶  Alex Yang-Hao Yu⁷ 

[1] Division of Chest, Department of Internal Medicine, Feng Yuan Hospital, Ministry of Health and Welfare, Taichung, Taiwan, ROC;Translational Medicine Research, China Medical University Hospital, Taichung, Taiwan, ROC;Welfare, Changhua Hospital, Changhua, Taiwan, ROC;Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan, ROC;Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC;Institute of Polymer Science and Engineering, National Taiwan University, Taipei, Taiwan, ROC;;Ministry of Health &

关键词: Epidermal growth factor receptor;    Gold nanoparticle (AuNP);    Small-interfering RNA (siRNA);    Lung cancer;   

DOI  :  

来源: DOAJ

【 摘 要 】

Epidermal growth factor receptor (EGFR), a critical factor promotes lung cancer cell proliferation and survival. Knockdown of EGFR expression thus promise beating lung cancer clinically. Functionalized gold nanoparticles may serve an effective vehicle carrying theranostic bio-active materials. Herein, physically gold nanoparticles were fabricated with biocompatible collagen to improve siRNA loading capacity carrying EGFR siRNA to treat lung cancer. Physic-chemical properties were comprehensively characterized for the collagen gold nanoparticle (C–Au), and with EGFR siRNA conjugation, C–Au-EGFRsi namely. Issues of biocompatibility were addressed. Interestingly, C–Au appeared more biocompatible to normal airway epithelial cells (BEAS-2B) than to cancer cells (A549) in terms of ROS production, cell cycle behavior, and cell growth influence. The C–Au demonstrated comparable or even more efficient, compared with lipofetamine, in carrying siRNA to knockdown EGFR of A549 cells. Endocytosis mediated cell entry for the collagen gold nanoparticles, and endosome-lysosomal pathway involved transporting and metabolizing these nanoparticles. In xenograft mice model, substantial tumor suppression effects were observed treating with C–Au-EGFRsi, in which tumor weight reduced 30% for lipofetamine carrier, and down to 70% for C–Au carrier. Particularly, overall survival rate was improved for both treatment groups with lipofetamine and C–Au carrier, respectively.

【 授权许可】

Unknown